Skip to main content
Get Alerts

Data Explorer

Research historical outbreak investigations and the full recall archive, with charts, trends, and advanced filters. Looking for what's happening right now instead? See current Health Alerts.

Recall totals

All FDA and USDA recalls in Public Health Trace, June 2012 to October 2026.

37,242
Total recall recordsAll FDA and USDA recalls in Public Health Trace
9,844
Class I recallsReasonable probability of serious health consequences
24,383
Class II recallsTemporary or medically reversible health consequences
2,897
Class III recallsNot likely to cause adverse health consequences

Quick insights

A snapshot of the most notable patterns across all recorded FDA and USDA recalls.

Most recalled product100 vegetarian Fenugreek Capsules 90 count, 600mg, packaged in 150cc Amber Glass Packer with White Polypropylene Cap. 53 recalls
Most common hazardLack of Assurance of Sterility 2,084 recalls
Newest recallhttp://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/krasnyi-oktyabr-inc-recalls-starfish-seafood-trio-because-possible-health-riskPublished October 9, 2026
Most affected stateHawaii 200 recalls mention this state

Download matching recalls as CSV

CSV exports include up to 5,000 matching rows (applying your current filters), not the full dataset if it's larger.

Filters
Recall details
Location
Date range
Sort results
Clear filters
Metric
View
Recalls announced by month (Year to date)

A chart of recalls grouped by month.

Download CSV

Source: FDA and USDA public dataLast updated

Summary (Year to date)

  • 1,739 recalls have been announced year to date.
  • Sep 2026 was 15% higher than the previous complete period (Aug 2026: 182).
  • The highest complete period was Jun 2026 (300).
  • Oct 2026 is incomplete and not included in the figures above.
  • Complete data
  • Incomplete
Recalls by class

A bar chart of the total number of recalls in this dataset by recall class.

Recalls by class
ClassRecalls
Class II24,383
Class I9,844
Class III2,897
Not Yet Classified2
Download CSV
Recalls by class
ClassRecalls
Class II24,383
Class I9,844
Class III2,897
Not Yet Classified2

Showing 20,541–20,560 of 21,420 recalls

FDA Recall OngoingHistorical recordClass II

Altrenogest 50 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Alprostadil 2000 mcg/ml, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Adenosine-Mono-Phosphate Injection, 200 mg/ml, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Acepromazine 25 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall OngoingHistorical recordClass II

Acetyl-D-Glucosamine w/Chondroitin 200 mg/ml, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: January 15, 2014Historical recordClass III

Camila (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tablets each, 28 day regimen, Rx Only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-0715-58

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: January 15, 2014Historical recordClass III

Errin (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tablets each, 28 day regimen, Rx Only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-0344-58

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: May 11, 2015Historical recordClass III

Folic Acid Injection, USP, 5 mg/mL, For IM, IV or SC Use, 10 mL, Multiple Dose Vial, Rx only, APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-184-11

by Fresenius Kabi USA, LLC

Reason
Failed Impurities/Degradation Specification
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: October 28, 2014Historical recordClass II

Gentamicin Sulfate Injection USP 80 mg/2 mL(40 mg/mL as Gentamicin), 2 mL Single-dose Fliptop Vial, (NDC 0409-1207-13), Rx only, Manufactured by Hospira, Inc, Lake Forest, IL 60046 USA.

by Hospira Inc.

Reason
Presence of Particulate Matter: visible particles were identified floating in the primary container.
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: October 27, 2015Historical recordClass II

Benztropine Mesylate Injection, USP, 2 mg/2 mL (1 mg/1 mL), 2 mL Single Dose Vial, Rx only, labeled as a) Manufactured for: APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-970-02; and b) Manufactured in the USA for Nexus Pharmaceuticals Inc., Vernon Hills, IL 60061, NDC 14789-300-02

by Fresenius Kabi USA, LLC

Reason
Presence of particulate matter: characterized as thin colorless flakes that are visually and chemically consistent with glass delamination observed in reserve sample vials
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: April 10, 2014Historical recordClass III

Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: April 10, 2014Historical recordClass III

Lessina(R) (Levonorgestrel and ethinyl estradiol tablets, USP) 0.1 mg/0.02 mg, 28 day regimen, Rx only, Barr Laboratories Inc., Pomona, NY --- NDC 0555-9014-67

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: February 22, 2017Historical recordClass II

Vancomycin 50 mg/ml, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907

by Clinical Specialties Compounding Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 10, 2013
Distribution
FL, GA and SC.

View recall →

FDA Recall TerminatedTerminated: February 22, 2017Historical recordClass II

Tetracaine(buffered) 0.25% solution, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907

by Clinical Specialties Compounding Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 10, 2013
Distribution
FL, GA and SC.

View recall →

FDA Recall TerminatedTerminated: February 22, 2017Historical recordClass II

Test cyp 75 mg-estradiol cyp 5 mg/ml, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907

by Clinical Specialties Compounding Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 10, 2013
Distribution
FL, GA and SC.

View recall →

FDA Recall TerminatedTerminated: February 22, 2017Historical recordClass II

Test Cyp 50 mg-estradiol blend 22 mg, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907

by Clinical Specialties Compounding Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 10, 2013
Distribution
FL, GA and SC.

View recall →

FDA Recall TerminatedTerminated: February 22, 2017Historical recordClass II

Test Cyp 50 mg-estradiol cyp 7 mg/ml, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907

by Clinical Specialties Compounding Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 10, 2013
Distribution
FL, GA and SC.

View recall →

FDA Recall TerminatedTerminated: February 22, 2017Historical recordClass II

Test Cyp 50 mg-estradiol cyp 2 mg/ml, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907

by Clinical Specialties Compounding Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 10, 2013
Distribution
FL, GA and SC.

View recall →

FDA Recall TerminatedTerminated: February 22, 2017Historical recordClass II

Test Cyp 50 mg-estradiol cyp 2 mg/ml, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907

by Clinical Specialties Compounding Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 10, 2013
Distribution
FL, GA and SC.

View recall →

FDA Recall TerminatedTerminated: February 22, 2017Historical recordClass II

Test cyp 50 mg/ml, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907

by Clinical Specialties Compounding Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 10, 2013
Distribution
FL, GA and SC.

View recall →

Data last updated:

Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions. Read the full medical disclaimer.